Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

STAT3 as a biomarker of progression in atypical nevi of patients with melanoma: dose-response effects of systemic IFNalpha therapy.

Wang W, Edington HD, Rao UN, Jukic DM, Wang H, Shipe-Spotloe JM, Kirkwood JM.

J Invest Dermatol. 2008 Aug;128(8):1997-2002. doi: 10.1038/jid.2008.26. Epub 2008 Feb 28.

2.

Modulation of signal transducers and activators of transcription 1 and 3 signaling in melanoma by high-dose IFNalpha2b.

Wang W, Edington HD, Rao UN, Jukic DM, Land SR, Ferrone S, Kirkwood JM.

Clin Cancer Res. 2007 Mar 1;13(5):1523-31.

3.
5.

Systemic interferon-alpha (IFN-alpha) treatment leads to Stat3 inactivation in melanoma precursor lesions.

Kirkwood JM, Farkas DL, Chakraborty A, Dyer KF, Tweardy DJ, Abernethy JL, Edington HD, Donnelly SS, Becker D.

Mol Med. 1999 Jan;5(1):11-20.

6.

Impact of IFNalpha2b upon pSTAT3 and the MEK/ERK MAPK pathway in melanoma.

Wang W, Edington HD, Jukic DM, Rao UN, Land SR, Kirkwood JM.

Cancer Immunol Immunother. 2008 Sep;57(9):1315-21. doi: 10.1007/s00262-008-0466-9. Epub 2008 Apr 3.

PMID:
18386001
7.

Methylthioadenosine phosphorylase represents a predictive marker for response to adjuvant interferon therapy in patients with malignant melanoma.

Meyer S, Wild PJ, Vogt T, Bataille F, Ehret C, Gantner S, Landthaler M, Klinkhammer-Schalke M, Hofstaedter F, Bosserhoff AK.

Exp Dermatol. 2010 Aug;19(8):e251-7. doi: 10.1111/j.1600-0625.2010.01072.x.

8.

Interferon-alpha treatment may negatively influence disease progression in melanoma patients by hyperactivation of STAT3 protein.

Humpoliková-Adámková L, Kovarík J, Dusek L, Lauerová L, Boudný V, Fait V, Fojtová M, Krejcí E, Kovarík A.

Eur J Cancer. 2009 May;45(7):1315-23. doi: 10.1016/j.ejca.2009.01.009. Epub 2009 Feb 14.

PMID:
19232485
9.

Cadherin expression pattern in melanocytic tumors more likely depends on the melanocyte environment than on tumor cell progression.

Krengel S, Grotelüschen F, Bartsch S, Tronnier M.

J Cutan Pathol. 2004 Jan;31(1):1-7.

PMID:
14675278
10.

Mcl-1, Bcl-XL and Stat3 expression are associated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma.

Zhuang L, Lee CS, Scolyer RA, McCarthy SW, Zhang XD, Thompson JF, Hersey P.

Mod Pathol. 2007 Apr;20(4):416-26.

11.

Minichromosome maintenance protein expression in benign nevi, dysplastic nevi, melanoma, and cutaneous melanoma metastases.

Boyd AS, Shakhtour B, Shyr Y.

J Am Acad Dermatol. 2008 May;58(5):750-4. doi: 10.1016/j.jaad.2007.12.026. Epub 2008 Feb 4.

PMID:
18249467
12.

Proto-oncogene c-kit expression in malignant melanoma: protein loss with tumor progression.

Montone KT, van Belle P, Elenitsas R, Elder DE.

Mod Pathol. 1997 Sep;10(9):939-44.

PMID:
9310959
13.

Activated stat-3 in melanoma.

Messina JL, Yu H, Riker AI, Munster PN, Jove RL, Daud AI.

Cancer Control. 2008 Jul;15(3):196-201.

14.

Dynamic balance of pSTAT1 and pSTAT3 in C57BL/6 mice infected with lethal or nonlethal Plasmodium yoelii.

Shi X, Qin L, Liu G, Zhao S, Peng N, Chen X.

Cell Mol Immunol. 2008 Oct;5(5):341-8. doi: 10.1038/cmi.2008.42.

15.

The initial steps of tumor progression in melanocytic lineage: a histochemical approach.

Wollina U, Kilian U, Henkel U, Schaarschmidt H, Knopf B.

Anticancer Res. 1991 Jul-Aug;11(4):1405-14.

PMID:
1746897
16.

Spitz nevi and atypical Spitz nevi/tumors: a histologic and immunohistochemical analysis.

Kapur P, Selim MA, Roy LC, Yegappan M, Weinberg AG, Hoang MP.

Mod Pathol. 2005 Feb;18(2):197-204.

17.

High-content pSTAT3/1 imaging assays to screen for selective inhibitors of STAT3 pathway activation in head and neck cancer cell lines.

Johnston PA, Sen M, Hua Y, Camarco D, Shun TY, Lazo JS, Grandis JR.

Assay Drug Dev Technol. 2014 Jan-Feb;12(1):55-79. doi: 10.1089/adt.2013.524. Epub 2013 Oct 15.

18.

Melanoma cells exhibit variable signal transducer and activator of transcription 1 phosphorylation and a reduced response to IFN-alpha compared with immune effector cells.

Lesinski GB, Trefry J, Brasdovich M, Kondadasula SV, Sackey K, Zimmerer JM, Chaudhury AR, Yu L, Zhang X, Crespin TR, Walker MJ, Carson WE 3rd.

Clin Cancer Res. 2007 Sep 1;13(17):5010-9.

19.

Melanoma biomarker expression in melanocytic tumor progression: a tissue microarray study.

Nazarian RM, Prieto VG, Elder DE, Duncan LM.

J Cutan Pathol. 2010 Apr;37 Suppl 1:41-7. doi: 10.1111/j.1600-0560.2010.01505.x.

PMID:
20482674
20.

Interferon Alpha Signalling and Its Relevance for the Upregulatory Effect of Transporter Proteins Associated with Antigen Processing (TAP) in Patients with Malignant Melanoma.

Heise R, Amann PM, Ensslen S, Marquardt Y, Czaja K, Joussen S, Beer D, Abele R, Plewnia G, Tampé R, Merk HF, Hermanns HM, Baron JM.

PLoS One. 2016 Jan 6;11(1):e0146325. doi: 10.1371/journal.pone.0146325. eCollection 2016.

Supplemental Content

Support Center